Boston, Massachusetts, United States
With over 10 years of experience spanning academia and industry, I focus on drug discovery and early development, including target validation, lead optimization, and preclinical IND-enabling studies to support regulatory filings. My dedication to scientific advancement extends to mentoring aspiring scientists, promoting knowledge-sharing, and inspiring the next generation of researchers.
At Novartis Institutes for BioMedical Research, I played a pivotal role within Oncology Pharmacology/Oncology Drug Discovery to advance the drug discovery pipeline through independent in vivo experiments. My work involved utilizing xenograft tumor mouse models to evaluate drug efficacy and pharmacokinetics, while also leveraging genetically engineered transgenic mouse models to enhance pharmacodynamics research. Collaborating with cross-functional teams allowed me to contribute to innovative drug candidate evaluations.
During my time at the Koch Institute for Integrated Cancer Research, I focused on self-amplifying RNA replicon technology, collaborating closely with Professor Darrell Irvine. This experience allowed me to enhance vaccine delivery methods and explore immunology applications, ultimately contributing to my Master's thesis on innovative cancer treatment strategies.
Thesis: Designing self-amplifying replicons for transient gene expression of interleukin-18 Thesis Director/Supervisor: Darrell Irvine
At Harvard Extension School, I contributed to research focused on mentoring, inclusion, and diversity in the sciences. Collaborating with faculty and students, I aimed to enhance the academic environment. My role involved analyzing data to uncover trends and best practices in science education, while honing my research methodologies and data analysis skills.
At the MIT Koch Institute for Integrative Cancer Research, I contributed to the advancement of vaccine technologies and immunotherapies. My role involved conducting laboratory experiments aimed at boosting immune responses against cancer. Working alongside a diverse team, I helped drive innovative research initiatives that are crucial for cancer treatment advancements.